Blackstone Inc
BBIO icon

Blackstone Inc’s BridgeBio Pharma BBIO Stock Holding History

Blackstone Inc’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$370K Buy
+4,963
New +$348K ﹤0.01% 411
2025
Q4 		– Sell
-20,361
Closed -$1.06M – 257
2025
Q3 		$1.06M Buy
+20,361
New +$993K ﹤0.01% 195

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Blackstone Inc's BBIO Position: Q2 2026 in Review

Blackstone Inc opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 4,963 shares worth $370K. The stake represents ﹤0.01% of the portfolio and ranks #411 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in BBIO as recently as Q3 2025.

Blackstone Inc first reported a position in BBIO in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.06M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Blackstone Inc held 4,963 shares of BridgeBio Pharma worth $370K as of Q2 2026.
  • BridgeBio Pharma was a new Blackstone Inc position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #411 holding.
  • Blackstone Inc first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 2 quarters since.
  • Blackstone Inc's BridgeBio Pharma position peaked at $1.06M in Q3 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.